Percentages of Specific Radionuclides Used in 2003 RDRC Studies by Imaging Type*
| Imaging nuclides | Nonimaging nuclides | ||||
|---|---|---|---|---|---|
| Positron (total = 77%) | γ (total = 5%) | β (total = 18%) | |||
| 11C | 37 | 99mTc | 2.50 | 3H | 12.40 |
| 18F | 19 | 123I | 1.30 | 14C | 4% |
| 15O | 17.50 | 131I | 0.30 | 59Fe | 0.70 |
| 13N | 2.60 | 133Xe | 0.30 | 45Ca | 0.30 |
| 60Cu | 0.70 | 111In | 0.20 | 55Fe | 0.30 |
| 17F | 0.50 | 125I | 0.30 | ||
| 94mTc | 0.20 | 47Ca | 0.20 | ||
| 65Zn | 0.20 | ||||
↵* Radioactive drug research studies conducted in 2003: 84 committees, 284 studies, 2,797 human subjects.
Values in alternate columns are expressed as percentages.